Innovation Pharmaceuticals Inc (IPIX)

[djs7]

http://www.ipharminc.com/new-blog/2020/5/21/brilacidin-for-covid-19-proposed-targets-and-mechanisms-of-action-against-sars-cov-2

In news released on Tuesday, the Company announced that in vitro research being independently conducted at a U.S. Regional Biocontainment Laboratory (RBL) revealed Brilacidin reduced the viral titer (load) of SARS-CoV-2, the novel coronavirus responsible for COVID-19, by 75 percent as compared to vehicle control after only 1 hour of preincubation prior to infection. The concentration of Brilacidin tested was 10µM.


Whereas Brilacidin, prior to infection, has the potential both to disrupt the virus directly and prevent viral entry into host cells, in addition to inhibiting viral replication post-infection—making for three distinct potential direct antiviral mechanisms of action.